112P Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience

58.2-72.2, and the real-world DCR was 85.1% (95% CI 79.2-89.9).Median PFS was 6.9 months (95% CI 5.8-7.2), with a 6-month PFS rate of 56.9% (95% CI 48.0-64.9).Median PFS was 5.4 months (95% CI 4.8-7.5) in patients with brain metastases and 7.0 months (95% CI 5.9-7.6) in those without brain metastases, without statistical difference (P0.110).OS data are not mature yet.Treatment-emergent adverse events (TEAEs) of any grade were reported in 166 (88.3%) patients, and grade 3 or worse TEAEs occurred in 60 (31.9%) patients.Conclusions: This real-world study enrolled a broader and more diverse SCLC patient population compared to the CAPSTONE-1 trial.Despite this, adebrelimab-based regimen showed favorable effectiveness and a manageable safety profile in the firstline setting for ES-SCLC, offering additional pivotal data to the CAPSTONE-1 trial.